MVR-T3011 Posts 100% RFS in BCG-Naïve NMIBC
SUZHOU, China, February 26, 2026 ImmVira Group announced encouraging preliminary clinical data for its oncolytic virus candidate MVR-T3011 in...
bladder cancer
Analgesic Allergy Labels Tied to Maternal Risks
MILWAUKEE, Feb. 21, 2026 — New research presented at the 2026 Annual Meeting of the American Academy of Allergy,...
ImmunityBio Expands ANKTIVA Access in Saudi Arabia
SAN DIEGO & RIYADH — February 20, 2026 — Immunotherapy innovator ImmunityBio has announced a strategic partnership with regional...
EU Clears ANKTIVA–BCG for Bladder Cancer Therapy
Conditional Approval Expands Access to 33 Countries February 18, 2026 | Culver City, California ImmunityBio announced that the European...
Merck Advances GU Cancer Care With New ASCO Data
RAHWAY, N.J., Feb. 12, 2026 — Merck & Co. announced the presentation of extensive new clinical data in bladder...
CG Oncology Advances Phase 3 Timeline for NMIBC Trial
IRVINE, California | January 9, 2026 — CG Oncology, Inc., a late-stage clinical biopharmaceutical company, has announced an accelerated...
INLEXZO Shows 74% One-Year Disease-Free Survival in High-Risk NMIBC
NEW BRUNSWICK, NJ — December 2025 — Johnson & Johnson announced new one-year results showing that its intravesical gemcitabine...
FDA Clears New KEYTRUDA Regimens for Bladder Cancer Care
Rahway, N.J., Nov. 21, 2025 — In a major advancement for oncology treatment, the U.S. Food and Drug Administration...